Kuros Biosciences (Switzerland) Performance
| KURN Stock | CHF 26.04 0.48 1.81% |
The company secures a Beta (Market Risk) of 0.61, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kuros Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kuros Biosciences is expected to be smaller as well. At this point, Kuros Biosciences has a negative expected return of -0.07%. Please make sure to verify Kuros Biosciences' maximum drawdown, potential upside, kurtosis, as well as the relationship between the value at risk and skewness , to decide if Kuros Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Kuros Biosciences AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Kuros Biosciences is not utilizing all of its potentials. The current stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Last Split Factor 1:100 | Dividend Date 2020-10-08 | Last Split Date 2016-06-23 |
1 | Can Kuros Biosciences AG stock surprise markets with earnings - Weekly Volume Report Risk Managed Investment Strategies - Newser | 12/05/2025 |
2 | Insiders own 24 percent of Kuros Biosciences AG shares but retail investors control 59 percent of the company - Yahoo Finance | 12/29/2025 |
3 | KURN.SW stock down 2.62 percent to CHF25.28 on SIX top losers signal - Meyka | 02/11/2026 |
| Begin Period Cash Flow | 14.2 M | |
| Total Cashflows From Investing Activities | -1.1 M |
Kuros |
Kuros Biosciences Relative Risk vs. Return Landscape
If you would invest 2,816 in Kuros Biosciences AG on November 22, 2025 and sell it today you would lose (164.00) from holding Kuros Biosciences AG or give up 5.82% of portfolio value over 90 days. Kuros Biosciences AG is generating negative expected returns and assumes 2.6173% volatility on return distribution over the 90 days horizon. Simply put, 23% of stocks are less volatile than Kuros, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Kuros Biosciences Target Price Odds to finish over Current Price
The tendency of Kuros Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 26.04 | 90 days | 26.04 | about 79.35 |
Based on a normal probability distribution, the odds of Kuros Biosciences to move above the current price in 90 days from now is about 79.35 (This Kuros Biosciences AG probability density function shows the probability of Kuros Stock to fall within a particular range of prices over 90 days) .
Kuros Biosciences Price Density |
| Price |
Predictive Modules for Kuros Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kuros Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Kuros Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Kuros Biosciences is not an exception. The market had few large corrections towards the Kuros Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Kuros Biosciences AG, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Kuros Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 0.61 | |
σ | Overall volatility | 1.82 | |
Ir | Information ratio | -0.03 |
Kuros Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kuros Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kuros Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Kuros Biosciences generated a negative expected return over the last 90 days | |
| Kuros Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 75.56 M. Net Loss for the year was (3.92 M) with profit before overhead, payroll, taxes, and interest of 91.68 M. | |
| About 28.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: KURN.SW stock down 2.62 percent to CHF25.28 on SIX top losers signal - Meyka |
Kuros Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Kuros Stock often depends not only on the future outlook of the current and potential Kuros Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kuros Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 37.2 M | |
| Cash And Short Term Investments | 17.5 M |
Kuros Biosciences Fundamentals Growth
Kuros Stock prices reflect investors' perceptions of the future prospects and financial health of Kuros Biosciences, and Kuros Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kuros Stock performance.
| Return On Equity | -0.0862 | ||||
| Return On Asset | 0.0257 | ||||
| Profit Margin | (0.06) % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 963.28 M | ||||
| Shares Outstanding | 39.18 M | ||||
| Price To Book | 12.78 X | ||||
| Price To Sales | 9.86 X | ||||
| Revenue | 75.56 M | ||||
| Gross Profit | 91.68 M | ||||
| EBITDA | (561 K) | ||||
| Net Income | (3.92 M) | ||||
| Cash And Equivalents | 18.33 M | ||||
| Cash Per Share | 1.22 X | ||||
| Total Debt | 1.79 M | ||||
| Current Ratio | 4.91 X | ||||
| Book Value Per Share | 1.90 X | ||||
| Cash Flow From Operations | 3.14 M | ||||
| Earnings Per Share | (0.15) X | ||||
| Market Capitalization | 1.02 B | ||||
| Total Asset | 84.54 M | ||||
| Retained Earnings | (45.43 M) | ||||
| Working Capital | 23.86 M | ||||
About Kuros Biosciences Performance
Evaluating Kuros Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Kuros Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kuros Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 229.37 | 134.64 | |
| Return On Tangible Assets | (0.09) | (0.09) | |
| Return On Capital Employed | (0.07) | (0.07) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.06) | (0.06) |
Things to note about Kuros Biosciences performance evaluation
Checking the ongoing alerts about Kuros Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kuros Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kuros Biosciences generated a negative expected return over the last 90 days | |
| Kuros Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 75.56 M. Net Loss for the year was (3.92 M) with profit before overhead, payroll, taxes, and interest of 91.68 M. | |
| About 28.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: KURN.SW stock down 2.62 percent to CHF25.28 on SIX top losers signal - Meyka |
- Analyzing Kuros Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kuros Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Kuros Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kuros Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kuros Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kuros Biosciences' stock. These opinions can provide insight into Kuros Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Kuros Stock Analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.